Leukapheresis Market By Type (Granulocyte Apheresis, Lymphocyte Apheresis, Monocyte Apheresis), Application (Therapeutic Leukapheresis, Cell Therapy, Immunotherapy, Research Application), & Region for 2024-2031

Leukapheresis Market Valuation – 2024-2031

Owing to an increase in the global prevalence of leukemia and other hematological illnesses drive the leukapheresis market. Leukapheresis, a therapeutic method that separates leukocytes from blood, is increasingly used in the treatment of various disorders because it allows for the selective removal of sick white blood cells while maintaining other blood components. Furthermore, the growing demand for personalized medicine and targeted therapies in oncology is driving the use of leukapheresis to collect leukocytes for downstream cellular therapy applications such as CAR-T cell therapy and adoptive immunotherapy, contributing to the market’s upward trajectory. The leukapheresis market is estimated to surpass a revenue of USD 71.39 Billion in 2024 and reach USD 114.48 Billion by 2031.

The leukapheresis market has seen significant growth, owing to technological developments and expanding uses across a variety of therapeutic domains. Leukapheresis, a method for separating white blood cells from blood, has seen advances in automated equipment, resulting in greater efficiency, precision, and patient comfort. These improvements have broadened the scope of leukapheresis beyond traditional uses in hematological illnesses and into developing areas such as cellular therapy, immunotherapy, and regenerative medicine. The market is expected to rise with a projected CAGR of 6.08% from 2024 to 2031.

Leukapheresis MarketDefinition/ Overview

Leukapheresis is a medical technique that separates white blood cells from a patient’s bloodstream. During leukapheresis, blood is taken from the patient using a catheter or needle and passed through a machine known as a leukapheresis device. This apparatus separates white blood cells from other blood components, such as red blood cells and platelets, according on their physical qualities. After isolating the white blood cells, the other blood components are returned to the patient’s blood. The future of leukapheresis, a method for collecting leukocytes (white blood cells) from the blood, is bright and multifaceted. With advances in medical technology and research, leukapheresis is poised to play a critical role in a variety of sectors, including immunotherapy, regenerative medicine, and cell-based therapies. Leukapheresis in immunotherapy allows for the extraction of immune cells, which can then be used to generate tailored cancer treatments and targeted therapeutics. Furthermore, in regenerative medicine, leukapheresis makes it easier to isolate and purify stem cells for tissue engineering and transplantation, which has the potential to treat a variety of diseases and injuries.

How is the Rising Geriatric Population and Advancements in Cell Therapy Set to Expand the Leukapheresis Market?

The increasing advancements in cell therapy and the rising geriatric population are expected to fuel the expansion of the leukapheresis market. As people age, they become more vulnerable to blood problems such leukemia, lymphoma, and autoimmune diseases. The prevalence of cancer rises with age, creating a greater demand for leukapheresis operations for both therapeutic and diagnostic purposes. There is an increasing demand for stem cell transplantation among the elderly to treat a variety of hematological and non-hematological illnesses. Leukapheresis is essential for obtaining hematopoietic stem cells from older donors or patients since it is less invasive and has fewer problems than standard bone marrow aspiration.

Immunotherapy, especially CAR-T cell therapy, is increasingly used to treat cancer, particularly hematologic malignancies. Leukapheresis is crucial in CAR-T cell treatment because it allows the collection of patient-derived white blood cells for genetic modification and subsequent reinfusion to target cancer cells. Leukapheresis techniques can help diagnose and monitor a variety of medical illnesses by isolating certain cell populations for study, especially given the older population’s increased susceptibility to infectious infections, autoimmune disorders, and other conditions.

Additionally, advances in cell treatment, notably CAR-T cell therapy, are leading to customized medical techniques suited to specific patients. Leukapheresis isolates and enriches patient-specific cell types, allowing cell-based therapies to be tailored for greater efficacy and safety. Technological advances in apheresis equipment have resulted in the creation of more efficient and automated leukapheresis systems. Automated systems with integrated leukocyte collection and processing capabilities simplify the leukapheresis operation, making it more accessible and practicable for a broader variety of patients, particularly the elderly.

The growing emphasis on cell-based therapeutics in pharmaceutical research and development fuels the demand for leukapheresis services and technology. Leukapheresis is required for separating subsets of white blood cells for research reasons such as assessing drug efficacy, monitoring immunological responses, and developing new therapeutic techniques.

How do Technical Expertise and the High Cost of Equipment Hamper the Leukapheresis Market?

Performing leukapheresis operations requires specialized training and competence. Healthcare facilities may struggle to hire and maintain qualified leukapheresis technicians. The paucity of qualified workers can limit the availability of leukapheresis treatments, especially in underprivileged areas or small healthcare facilities.

Leukapheresis techniques need the use of sophisticated equipment and the execution of intricate protocols. Healthcare workers must be thoroughly trained to operate leukapheresis machines, manage potential difficulties, and ensure patient safety. The technical difficulty of leukapheresis operations may deter healthcare professionals from providing these services, particularly if they lack the required expertise or finances. The training and education of healthcare staff in leukapheresis techniques incurs additional expenditures for healthcare facilities, including expenses for specific training programs, workshops, and certification exams. Some healthcare institutions, particularly those with limited finances or resources, may find it prohibitively expensive to provide this training.

Furthermore, healthcare providers may be hesitant to invest in leukapheresis equipment and training due to worries about the ROI and the difficulty of integrating leukapheresis services into existing workflows. The perceived learning curve for leukapheresis operations may deter healthcare practitioners from implementing these techniques into their clinical practice. The high cost of leukapheresis equipment and treatments can be a considerable financial burden for patients, especially those who do not have enough insurance coverage or access to healthcare financing. Patients may be unable to pay leukapheresis treatments, resulting in unequal access to therapy and health outcomes.

Additionally, the leukapheresis market is distinguished by a wide range of equipment manufacturers and technological platforms, resulting in variations in product features, performance, and compatibility. The absence of standardization in leukapheresis equipment and methods might complicate healthcare providers’ purchasing decisions and impede interoperability between systems.

Leukapheresis operations can be time-consuming and uncomfortable for patients, which may lead to noncompliance or reluctance to complete subsequent procedures. A dependable supply chain for consumables, such as disposable leukapheresis kits and filters, is critical for the continuous provision of leukapheresis services. Logistics issues might affect accessibility and affordability. Ethical difficulties may arise when using leukapheresis for uses, such as stem cell transplantation or cell-based therapy. Ensuring informed consent and ethical standards is critical.

Category-Wise Acumens

How does the Increasing Demand for Therapeutic Leukapheresis Bolt up the Growth of the Leukapheresis Market?

The increasing demand for therapeutic leukapheresis reflects its importance as a valuable therapeutic modality in addressing a diverse range of medical conditions. Therapeutic leukapheresis is used to treat a wide range of medical conditions, including hematologic disorders (such as leukemia and lymphoma), autoimmune diseases (such as multiple sclerosis and rheumatoid arthritis), and transplant complications (such as graft-versus-host disease). As our understanding of disease pathophysiology grows and new treatment indications emerge, the breadth of therapeutic leukapheresis expands, resulting in an increase in demand for leukapheresis procedures.

Therapeutic leukapheresis has been shown to be clinically beneficial in treating a variety of illnesses by selectively removing disease-causing components from the bloodstream. For example, leukapheresis can help reduce increased white blood cell counts in leukemia patients and eliminate autoantibodies in autoimmune illnesses. Positive clinical outcomes and evidence of efficacy contribute to the growing acceptance and implementation of leukapheresis as either a standard or adjunctive therapy in clinical practice. The prevalence of diseases treatable or manageable with leukapheresis, such as hematologic malignancies, autoimmune disorders, and organ transplant problems, is increasing globally. Aging populations, lifestyle changes, environmental effects, and improved diagnostic skills all contribute to the increasing burden of chronic diseases, driving need for treatment procedures such as leukapheresis.

Furthermore, advances in leukapheresis equipment technology, including improvements to apheresis machines, disposable kits, and software interfaces, contribute to the safety, efficiency, and ease of executing leukapheresis treatments. Continuous-flow systems, automated leukocyte collection, and closed-system processing are examples of leukapheresis technology innovations that lead to increased procedural throughput, less operator dependency, and improved patient outcomes, all of which promote demand growth.

Additionally, investments in healthcare infrastructure, such as expanding apheresis centres, training healthcare personnel, and providing supportive services (such as transfusion medicine and haematology/oncology expertise), make it easier to provide leukapheresis services to a larger patient population. Improved access to leukapheresis facilities and services, particularly in underserved areas or emerging countries, helps to drive market growth and meet the growing need for therapeutic interventions.

Will the Rising Utilization of Cell Therapy and Immunotherapy Contribute to the Positive Momentum of the Leukapheresis Market?

The rising utilization of cell therapy and immunotherapy represents a significant opportunity for the leukapheresis market. Cell therapy, known for the use of living cells to treat diseases in a variety of medical sectors including oncology, regenerative medicine, and autoimmune disorders, has emerged as a viable technique. Similarly, immunotherapy, a type of cell therapy that uses the body’s immune system to treat diseases such as cancer, has shown extraordinary efficacy in some patient populations. Leukapheresis methods are frequently used to harvest specific immune cell types, such as T cells, dendritic cells, and natural killer (NK) cells.

Leukapheresis, a crucial enabling technique, plays an important role in the manufacture of cell-based treatments and immunotherapies by extracting and enriching the required cell populations from the patient’s blood. This approach allows for efficient and safe acquisition of therapeutic cell populations for subsequent processing and infusion, with the selective collection of target cells while returning other blood components to the patient. Cell therapy and immunotherapy are increasingly being used to treat a wide range of diseases, including malignancies (e.g., leukemia, lymphoma, solid tumours), autoimmune disorders (e.g., multiple sclerosis, rheumatoid arthritis), and infectious infections. As novel therapeutic targets are identified and treatment protocols are perfected, the demand for leukapheresis treatments to support sophisticated medicines is projected to rise.

Furthermore, technological improvements in leukapheresis equipment and techniques, including as automated cell separation systems, closed-system processing, and real-time monitoring capabilities, have a significant impact on the efficiency, safety, and repeatability of cell collection protocols. These advancements help to reduce procedural complexity, operator variability, and cell yields, making leukapheresis more easily integrated into the cell therapy and immunotherapy process.

Additionally, the increased use of cell treatment and immunotherapy increases demand for leukapheresis services, resulting in market expansion and revenue growth for manufacturers, service providers, and healthcare facilities. Collaboration among industry stakeholders, such as biopharmaceutical companies, academic institutions, and healthcare providers, promotes innovation, speeds up clinical development, and broadens patient access to breakthrough medicines enabled by leukapheresis.

Gain Access into Leukapheresis Market Report Methodology

Country/Region-wise Acumens

Will the Advanced Healthcare Infrastructure and Academic Research in North America Foster the Leukapheresis Market Further?

The increasing and advanced healthcare infrastructure and robust academic research ecosystem in North America create a supportive environment for the continued growth of the leukapheresis market. Many cutting-edge hospitals and medical institutes in North America use cutting-edge technology, such as advanced leukapheresis machines. Complex leukapheresis operations are carried out safely and efficiently at these institutions. The presence of specialist apheresis centres and blood component collecting units increases the ability to perform leukapheresis treatments, fulfilling the growing demand from many medical sectors.

North America is home to numerous notable research organizations and universities that fuel medical science innovation. These universities do extensive research on cell therapy, immunotherapy, and regenerative medicine, frequently collecting cells using leukapheresis. North America has many clinical trials for innovative therapeutics, with leukapheresis routinely used to collect cells, evaluate new treatment regimens, and create data supporting the efficacy and safety of newer medications. Collaborative research among academia, industry, and healthcare providers accelerates the development of new leukapheresis procedures and applications, resulting in technological and treatment advances.

Furthermore, government organizations, private foundations, and business grants provide significant financing for leukapheresis research and development. These financial resources support constant innovation and progress. The presence of regulatory agencies such as the FDA guarantees that novel leukapheresis technologies and therapies are rigorously evaluated and approved, while maintaining high safety and efficacy standards, which builds confidence in the use of leukapheresis. Extensive training programs and educational endeavours ensure that healthcare workers are knowledgeable about leukapheresis techniques, which is critical for the effective and safe performance of leukapheresis treatments.

Additionally, continuous advances in leukapheresis equipment, such as automated systems and improved cell separation technologies, improve procedural efficiency and results. These technical advances are frequently driven by North American businesses and research institutions. The use of data analytics and real-time monitoring into leukapheresis treatments enhances patient outcomes and operational efficiency, allowing for more accurate tracking and optimization of the process.

In North America, leukapheresis operations are frequently covered by comprehensive health insurance, including Medicare and Medicaid, making them available to a larger patient population. Strong patient advocacy groups in North America create awareness about the benefits of leukapheresis, encouraging its adoption and use in a variety of therapeutic settings.

Will the Rising Biotechnology Sectors and Economy in Asia Pacific Region Enrich the Growth Leukapheresis Market?

The rising biotechnology sectors and robust economic growth in the Asia-Pacific region create a fertile environment for the expansion of the leukapheresis market. The biotechnology sector in Asia-Pacific is seeing significant investment in research and development, which is propelling the development of novel medicines that require leukapheresis for cell collection. China, Japan, South Korea, and India are major biotechnology research hubs, with several businesses working on cell therapy, immunotherapy, and regenerative medicine.

A growing number of clinical trials for new biopharmaceuticals in the region use leukapheresis-based medicines, increasing demand for leukapheresis procedures and equipment. Local and worldwide collaborations help to accelerate the research and approval of new medicines, increasing the demand for leukapheresis. Advances in biomanufacturing technology and infrastructure in Asia-Pacific enable the creation of complex biological products. Many of these items’ supply chains rely heavily on leukapheresis.

Furthermore, modern manufacturing facilities for cell-based therapies are being built to increase the region’s ability to fulfil rising demand. Strong economic growth in many Asian-Pacific countries leads to increased healthcare spending. Both governments and the business sector are increasing their investments in healthcare infrastructure, technology, and services. Increased healthcare funds enable the implementation of modern medical procedures, such as leukapheresis. Economic development improves access to healthcare services for a greater proportion of the population.

Additionally, advanced leukapheresis therapies can benefit a larger number of patients. Expanding healthcare coverage and insurance systems makes expensive operations like leukapheresis more affordable and accessible. The rapidly expanding private healthcare industry in Asia-Pacific is critical to the adoption of modern medical technologies. Private hospitals and clinics frequently take the lead in implementing novel treatments. The expansion of medical tourism, notably in India, Thailand, and Malaysia, is driving up demand for cutting-edge operations such as leukapheresis.

Economic growth enables increased funding for healthcare professional education and training programs, maintaining a consistent supply of qualified workers capable of executing leukapheresis. Improved training programs raise the quality of care and broaden the availability of leukapheresis services.

Competitive Landscape

The leukapheresis market’s competitive landscape includes rising biotech enterprises, specialized equipment manufacturers, and regional healthcare providers. To increase market share, these organizations are focusing more on innovative technology and expanding their service offerings. Smaller companies are investing in research and development to create new leukapheresis devices and processes, with the goal of increasing efficiency, safety, and patient outcomes. Furthermore, regional healthcare providers are expanding their ability to deliver leukapheresis services in response to rising demand for cell treatments and immunotherapy.

Some of the prominent players operating in the leukapheresis market include

• Fresenius SE & Co. KGaA
• Terumo BCT, Inc.
• Asahi Kasei Medical Co., Ltd.
• Haemonetics Corporation
• Miltenyi Biotec GmbH
• Macopharma SA
• STEMCELL Technologies Inc.
• Guangzhou Daji Medical Science
• Technology Co., Ltd.

Latest Developments

• In May 2022, Fresenius Kabi closed the acquisition of Ivenix, Inc. (“Ivenix”), a specialized infusion therapy company. Ivenix adds a next-generation infusion therapy platform for the significant U.S. market to Fresenius Kabi’s portfolio and provides the company with key capabilities in hospital connectivity and interoperability. This creates new options in the large and growing infusion therapy market. The combination of Ivenix’ leading hardware and software products with Fresenius Kabi’s offering in intravenous fluids and infusion devices will create a comprehensive and leading setup of premium products. This forms a strong, accelerated basis to enable sustainable growth in the high-value MedTech space.
• In August 2022, Fresenius Medical Care, the world’s leading provider of products and services for individuals with kidney diseases, has closed the three-way merger including Fresenius Health Partners, the value-based care division of Fresenius Medical Care North America. The new company, which will operate under the InterWell Health brand, brings together Fresenius Health Partners’ expertise in kidney care value-based contracting and performance, InterWell Health’s clinical care models and strong network of 1,700 nephrologists and Cricket Health’s tech-enabled care model that utilizes its proprietary informatics, StageSmart™️ and patient engagement platforms to create an innovative, stand-alone entity poised to transform kidney care.

Report Scope